PL3560953T3 - Komórka - Google Patents

Komórka

Info

Publication number: PL3560953T3
Authority: PL; Poland
Prior art keywords: cell
Prior art date: 2014-12-24

Application number

PL19172397.2T

Other languages

English (en)

Inventor

Martin PULÉ

Shaun CORDOBA

Shimobi ONUOHA

Simon Thomas

Original Assignee

Autolus Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-24

Filing date

2015-12-23

Publication date

2024-05-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3560953(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-23 Application filed by Autolus Limited filed Critical Autolus Limited

2024-05-13 Publication of PL3560953T3 publication Critical patent/PL3560953T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)

PL19172397.2T 2014-12-24 2015-12-23 Komórka PL3560953T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB201423172		2014-12-24

Publications (1)

Publication Number	Publication Date
PL3560953T3 true PL3560953T3 (pl)	2024-05-13

Family

ID=55066668

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15817520T PL3237442T3 (pl)	2014-12-24	2015-12-23	Komórka
PL19172397.2T PL3560953T3 (pl)	2014-12-24	2015-12-23	Komórka

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15817520T PL3237442T3 (pl)	2014-12-24	2015-12-23	Komórka

Country Status (26)

Country	Link
US (8)	US11091532B2 (pl)
EP (3)	EP3560953B1 (pl)
JP (5)	JP6633081B2 (pl)
KR (6)	KR102085349B1 (pl)
CN (2)	CN114107212A (pl)
AU (5)	AU2015370679C1 (pl)
BR (1)	BR112017013690A2 (pl)
CA (2)	CA2970440A1 (pl)
CL (3)	CL2017001314A1 (pl)
DK (2)	DK3237442T3 (pl)
ES (2)	ES2744910T3 (pl)
FI (1)	FI3560953T3 (pl)
HR (1)	HRP20240357T1 (pl)
HU (2)	HUE046262T2 (pl)
IL (4)	IL274903B (pl)
LT (1)	LT3560953T (pl)
MX (1)	MX2017006233A (pl)
PL (2)	PL3237442T3 (pl)
PT (2)	PT3560953T (pl)
RS (1)	RS65343B1 (pl)
RU (2)	RU2022102250A (pl)
SG (2)	SG11201704084VA (pl)
SI (1)	SI3560953T1 (pl)
SM (1)	SMT202400134T1 (pl)
WO (1)	WO2016102965A1 (pl)
ZA (1)	ZA201703381B (pl)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150320799A1 (en)	2012-12-20	2015-11-12	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201415347D0 (en) *	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
CN114107212A (zh)	2014-12-24	2022-03-01	奥托路斯有限公司	细胞
LT3253865T (lt) *	2015-02-06	2022-11-10	National University Of Singapore	Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
GB201503742D0 (en)	2015-03-05	2015-04-22	Ucl Business Plc	Chimeric antigen receptor
AU2016226022B2 (en)	2015-03-05	2020-07-09	Fred Hutchinson Cancer Center	Immunomodulatory fusion proteins and uses thereof
IL254817B2 (en) *	2015-04-08	2023-12-01	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
GB201507115D0 (en) *	2015-04-27	2015-06-10	Ucl Business Plc	Nucleic Acid Construct
GB201507119D0 (en) *	2015-04-27	2015-06-10	Ucl Business Plc	Nucleic Acid Construct
CN115058395B (zh)	2015-06-25	2025-07-18	美商生物细胞基因治疗有限公司	嵌合抗原受体(car)、组合物及其使用方法
US11173179B2 (en)	2015-06-25	2021-11-16	Icell Gene Therapeutics Llc	Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
CA3019835A1 (en)	2016-04-08	2017-10-12	Purdue Research Foundation	Methods and compositions for car t cell therapy
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
GB201610515D0 (en) *	2016-06-16	2016-08-03	Autolus Ltd	Cell
CA3029197A1 (en)	2016-06-24	2017-12-28	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars), compositions and methods thereof
EP3507304B1 (en) *	2016-09-02	2024-04-03	Lentigen Technology, Inc.	Compositions and methods for treating cancer with duocars
JP7467117B2 (ja)	2016-10-07	2024-04-15	ノバルティスアーゲー	癌の治療のためのキメラ抗原受容体
CA3043752A1 (en)	2016-11-22	2018-05-31	National University Of Singapore	Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
CN110352068A (zh)	2016-12-02	2019-10-18	南加利福尼亚大学	合成的免疫受体及其使用方法
EP3556772A4 (en) *	2016-12-13	2020-09-09	Carsgen Therapeutics Ltd	HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
EP3567049A4 (en) *	2016-12-28	2020-08-26	Green Cross Lab Cell Corporation	CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
EP3568466A4 (en)	2017-01-10	2020-07-15	The General Hospital Corporation	TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
CN110612119B (zh)	2017-02-07	2024-10-29	西雅图儿童医院（Dba西雅图儿童研究所）	磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
CN110582288B (zh)	2017-02-28	2024-09-20	恩多塞特公司	用于car t细胞疗法的组合物和方法
US11725210B2 (en)	2017-03-17	2023-08-15	Fred Hutchinson Cancer Center	Immunomodulatory fusion proteins and uses thereof
WO2018191748A1 (en) *	2017-04-14	2018-10-18	The General Hospital Corporation	Chimeric antigen receptor t cells targeting the tumor microenvironment
ES2905377T3 (es) *	2017-04-18	2022-04-08	Autolus Ltd	Célula
KR20190142775A (ko)	2017-04-19	2019-12-27	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	조작된 항원 수용체를 발현하는 면역 세포
EP3625261A1 (en) *	2017-05-15	2020-03-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Bicistronic chimeric antigen receptors and their uses
SG10202109108UA (en)	2017-06-21	2021-09-29	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars), compositions and methods thereof
WO2019025800A1 (en) *	2017-08-02	2019-02-07	Autolus Limited	CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
US20190038733A1 (en)	2017-08-10	2019-02-07	National University Of Singapore	T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN109385402A (zh) *	2017-08-11	2019-02-26	上海恒润达生生物科技有限公司	一种等比例混合两种靶点cart细胞的制备方法及应用
CN107446937B (zh) *	2017-09-05	2020-12-25	深圳华云生物技术有限公司	嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
JP7654240B2 (ja)	2017-09-19	2025-04-01	マサチューセッツインスティテュートオブテクノロジー	キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
JP7275118B2 (ja) *	2017-10-16	2023-05-17	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
US11649294B2 (en)	2017-11-14	2023-05-16	GC Cell Corporation	Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109988242A (zh) *	2018-01-02	2019-07-09	武汉波睿达生物科技有限公司	联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN108101994B (zh) *	2018-01-04	2020-09-15	广东万海细胞生物科技有限公司	抗cd19抗体及其应用
BR112020014913A2 (pt)	2018-01-22	2020-12-08	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Métodos para uso de células t car
BR112020015884A2 (pt)	2018-02-06	2020-12-08	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
US20210038646A1 (en) *	2018-02-12	2021-02-11	The General Hospital Corporation	Chimeric antigen receptors targeting the tumor microenvironment
CN110157738B (zh) *	2018-02-13	2023-06-27	亘喜生物科技（上海）有限公司	靶向cd19和cd22的工程化免疫细胞及其应用
US12473336B2 (en)	2018-02-21	2025-11-18	Board Of Regents, The University Of Texas System	Methods for activation and expansion of natural killer cells and uses thereof
EP3755366A4 (en)	2018-02-23	2021-12-29	Endocyte, Inc.	Sequencing method for car t cell therapy
GB201807870D0 (en)	2018-05-15	2018-06-27	Autolus Ltd	A CD79-specific chimeric antigen receptor
JP7335272B2 (ja) *	2018-05-15	2023-08-29	オートラスリミテッド	キメラ抗原受容体
JP7584299B2 (ja)	2018-05-23	2024-11-15	ナショナルユニバーシティオブシンガポール	Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
CN112334479A (zh) *	2018-07-13	2021-02-05	南京传奇生物科技有限公司	用于治疗感染性疾病的共受体系统
PL3856775T3 (pl)	2018-09-27	2025-06-09	Autolus Limited	Chimeryczny receptor antygenowy
BR112021004383A2 (pt)	2018-09-28	2021-08-03	Massachusetts Institute Of Technology	proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
GB201816522D0 (en)	2018-10-10	2018-11-28	Autolus Ltd	Methods and reagents for analysing nucleic acids from single cells
GB201820547D0 (en) *	2018-12-17	2019-01-30	Oxford Univ Innovation	Modified antibodies
CA3131839A1 (en)	2019-03-08	2020-09-17	Autolus Limited	Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en)	2019-03-08	2019-04-24	Autolus Ltd	Method
JP2022533621A (ja) *	2019-05-16	2022-07-25	ナンジンレジェンドバイオテックカンパニー，リミテッド	認識分子を含む操作された免疫細胞
AU2020286471B2 (en) *	2019-06-07	2025-07-31	The Trustees Of The University Of Pennsylvania	Dual CAR expressing T cells individually linked to CD28 and 4-1BB
CN114258398A (zh)	2019-06-13	2022-03-29	总医院公司	工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
EP3990491A1 (en)	2019-06-26	2022-05-04	Massachusetts Institute of Technology	Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021009510A1 (en)	2019-07-16	2021-01-21	Autolus Limited	Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en)	2019-07-16	2019-08-28	Autolus Ltd	Method
AU2020325315A1 (en)	2019-08-07	2022-03-24	Aqualung Therapeutics Corp.	Anti-NAMPT antibodies and uses thereof
CN112390891B (zh) *	2019-08-14	2022-06-03	苏州方德门达新药开发有限公司	嵌合抗原受体及其构建方法和应用
CN110903401A (zh) *	2019-11-20	2020-03-24	浙江大学	一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
IL292924A (en) *	2019-11-26	2022-07-01	Novartis Ag	Cd19 and cd22 chimeric antigen receptors and uses thereof
MX2022006391A (es)	2019-11-26	2022-06-24	Novartis Ag	Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
CA3169804A1 (en) *	2020-02-04	2021-08-12	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
AU2021233158A1 (en) *	2020-03-11	2022-09-29	Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol (Igtp)	CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
US20210340524A1 (en)	2020-05-01	2021-11-04	Massachusetts Institute Of Technology	Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en)	2020-05-01	2025-10-07	Massachusetts Institute Of Technology	Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
GB202006820D0 (en) *	2020-05-07	2020-06-24	Autolus Ltd	Cell
TW202214844A (zh)	2020-06-17	2022-04-16	美商健生生物科技公司	用於製造多能幹細胞之材料及方法
IL300001A (en)	2020-07-24	2023-03-01	Massachusetts Gen Hospital	Enhanced virus-like particles and methods of use thereof for delivery to cells
AU2021333653A1 (en) *	2020-08-25	2023-03-23	Cytoimmune Therapeutics, Inc.	Bispecific antibody car cell immunotherapy
CA3201621A1 (en)	2020-12-03	2022-06-09	Century Therapeutics, Inc.	Genetically engineered cells and uses thereof
US11661459B2 (en)	2020-12-03	2023-05-30	Century Therapeutics, Inc.	Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112481284B (zh) *	2020-12-07	2023-07-25	深圳瑞吉生物科技有限公司	一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
JP2024500847A (ja)	2020-12-18	2024-01-10	センチュリーセラピューティクス，インコーポレイテッド	適合可能な受容体特異性を有するキメラ抗原受容体システム
KR102393776B1 (ko)	2020-12-30	2022-05-04	(주)이노베이션바이오	Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
US20230174651A1 (en)	2021-06-23	2023-06-08	Janssen Biotech, Inc.	Materials and methods for hinge regions in functional exogenous receptors
WO2023016554A1 (zh) *	2021-08-13	2023-02-16	上海医药集团股份有限公司	靶向cd22的抗原结合蛋白及其用途
KR102829757B1 (ko) *	2021-11-17	2025-07-09	(주)이노베이션바이오	인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
JP2025516531A (ja)	2022-05-11	2025-05-30	オートラスリミテッド	高リスクまたは再発性小児急性リンパ芽球性白血病のｃｄ１９／２２ｃａｒｔ細胞処置
US20250188492A1 (en)	2022-07-22	2025-06-12	Janssen Biotech, Inc.	Enhanced Transfer of Genetic Instructions to Effector Immune Cells
US20240197780A1 (en) *	2022-12-19	2024-06-20	Development Center For Biotechnology	Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers
WO2024196796A1 (en) *	2023-03-17	2024-09-26	Cartesian Therapeutics, Inc.	Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2024246526A1 (en)	2023-05-30	2024-12-05	Autolus Limited	Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2024250037A1 (en) *	2023-06-02	2024-12-05	Northeastern University	Targeted immune cell therapy utilizing trail and tnf mediated apoptosis
WO2025088308A1 (en)	2023-10-23	2025-05-01	Autolus Limited	Products and methods for treating autoimmune diseases
GB202403564D0 (en)	2024-03-12	2024-04-24	Autolus Ltd	Method
WO2025215360A1 (en)	2024-04-09	2025-10-16	Autolus Limited	Method
WO2025231185A1 (en)	2024-05-01	2025-11-06	Legend Biotech Ireland Limited	Viral glycoprotein variants and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2299011A1 (fr)	1975-01-29	1976-08-27	Obert Jean Claude	Generateur d'aerosols de part
EP1171596A1 (en)	1999-04-16	2002-01-16	Celltech Therapeutics Limited	Synthetic transmembrane components
GB9908807D0 (en)	1999-04-16	1999-06-09	Celltech Therapeutics Ltd	Synthetic signalling molecules
JP5312721B2 (ja) *	2000-11-07	2013-10-09	シティ・オブ・ホープ	Ｃｄ１９特異的再指向免疫細胞
WO2004106381A1 (en) *	2003-05-31	2004-12-09	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20130266551A1 (en)	2003-11-05	2013-10-10	St. Jude Children's Research Hospital, Inc.	Chimeric receptors with 4-1bb stimulatory signaling domain
DK1976886T3 (en)	2005-12-16	2015-03-02	Amgen Res Munich Gmbh	Means and methods for the treatment of tumor diseases
US9206440B2 (en) *	2009-01-23	2015-12-08	Roger Williams Hospital	Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
ES2654060T3 (es)	2011-10-20	2018-02-12	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Receptores de antígenos quiméricos anti-CD22
EP3594245A1 (en) *	2012-02-13	2020-01-15	Seattle Children's Hospital d/b/a Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
CN103483452B (zh)	2012-06-12	2021-08-13	上海细胞治疗集团有限公司	双信号独立的嵌合抗原受体及其用途
AU2013289971A1 (en)	2012-07-13	2015-01-22	The Trustees Of The University Of Pennsylvania	Enhancing activity of CAR T cells by co-introducing a bispecific antibody
EP3597215A1 (en)	2012-10-02	2020-01-22	Memorial Sloan-Kettering Cancer Center	Compositions and methods for immunotherapy
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
ES2718903T3 (es) *	2012-10-24	2019-07-05	Us Health	Receptores de antígenos quiméricos M971
WO2014124143A1 (en) *	2013-02-06	2014-08-14	Anthrogenesis Corporation	Modified t lymphocytes having improved specificity
EP3456818B1 (en)	2013-03-07	2020-05-20	Baylor College of Medicine	Targeting cd138 in cancer
EP3623380B1 (en)	2013-03-15	2025-10-22	Novartis AG	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2904265C (en)	2013-03-15	2023-08-08	Victor D. FEDOROV	Compositions and methods for immunotherapy
LT3546572T (lt)	2013-05-13	2024-05-27	Cellectis	Cd19 specifinis chimerinis antigeno receptorius ir jo panaudojimas
EP3021853A1 (en)	2013-07-18	2016-05-25	Baylor College Of Medicine	Method of enhancing potency of immune cells
DK3071222T3 (da) *	2013-11-21	2020-11-16	Ucl Business Ltd	Celle
US10239948B2 (en)	2013-12-20	2019-03-26	Cellectis	Method of engineering multi-input signal sensitive T cell for immunotherapy
CN114107212A (zh)	2014-12-24	2022-03-01	奥托路斯有限公司	细胞
GB201503742D0 (en)	2015-03-05	2015-04-22	Ucl Business Plc	Chimeric antigen receptor
GB201507111D0 (en)	2015-04-27	2015-06-10	Ucl Business Plc	Nucleic acid construct
CN115058395B (zh) *	2015-06-25	2025-07-18	美商生物细胞基因治疗有限公司	嵌合抗原受体(car)、组合物及其使用方法
GB201518816D0 (en) *	2015-10-23	2015-12-09	Autolus Ltd	Receptor
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
GB201610515D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Cell
GB201807870D0 (en)	2018-05-15	2018-06-27	Autolus Ltd	A CD79-specific chimeric antigen receptor
JP7335272B2 (ja)	2018-05-15	2023-08-29	オートラスリミテッド	キメラ抗原受容体

2015
- 2015-12-23 CN CN202111208410.1A patent/CN114107212A/zh active Pending
- 2015-12-23 PL PL15817520T patent/PL3237442T3/pl unknown
- 2015-12-23 KR KR1020177019393A patent/KR102085349B1/ko active Active
- 2015-12-23 AU AU2015370679A patent/AU2015370679C1/en active Active
- 2015-12-23 CN CN201580065695.4A patent/CN107002045B/zh active Active
- 2015-12-23 EP EP19172397.2A patent/EP3560953B1/en active Active
- 2015-12-23 ES ES15817520T patent/ES2744910T3/es active Active
- 2015-12-23 SM SM20240134T patent/SMT202400134T1/it unknown
- 2015-12-23 DK DK15817520.8T patent/DK3237442T3/da active
- 2015-12-23 KR KR1020217024459A patent/KR102376244B1/ko active Active
- 2015-12-23 PT PT191723972T patent/PT3560953T/pt unknown
- 2015-12-23 BR BR112017013690-2A patent/BR112017013690A2/pt not_active Application Discontinuation
- 2015-12-23 SG SG11201704084VA patent/SG11201704084VA/en unknown
- 2015-12-23 KR KR1020217024458A patent/KR102376242B1/ko active Active
- 2015-12-23 HU HUE15817520A patent/HUE046262T2/hu unknown
- 2015-12-23 MX MX2017006233A patent/MX2017006233A/es active IP Right Grant
- 2015-12-23 PT PT15817520T patent/PT3237442T/pt unknown
- 2015-12-23 EP EP15817520.8A patent/EP3237442B1/en not_active Revoked
- 2015-12-23 FI FIEP19172397.2T patent/FI3560953T3/fi active
- 2015-12-23 ES ES19172397T patent/ES2976197T3/es active Active
- 2015-12-23 IL IL274903A patent/IL274903B/en unknown
- 2015-12-23 KR KR1020237036909A patent/KR20230152824A/ko active Pending
- 2015-12-23 WO PCT/GB2015/054137 patent/WO2016102965A1/en not_active Ceased
- 2015-12-23 PL PL19172397.2T patent/PL3560953T3/pl unknown
- 2015-12-23 KR KR1020227031979A patent/KR20220129684A/ko not_active Ceased
- 2015-12-23 EP EP23217769.1A patent/EP4368704A3/en active Pending
- 2015-12-23 IL IL301458A patent/IL301458A/en unknown
- 2015-12-23 LT LTEP19172397.2T patent/LT3560953T/lt unknown
- 2015-12-23 IL IL292508A patent/IL292508B2/en unknown
- 2015-12-23 HR HRP20240357TT patent/HRP20240357T1/hr unknown
- 2015-12-23 JP JP2017533969A patent/JP6633081B2/ja active Active
- 2015-12-23 SG SG10202111107RA patent/SG10202111107RA/en unknown
- 2015-12-23 KR KR1020197038792A patent/KR20200003939A/ko not_active Ceased
- 2015-12-23 US US15/529,690 patent/US11091532B2/en active Active
- 2015-12-23 DK DK19172397.2T patent/DK3560953T5/da active
- 2015-12-23 CA CA2970440A patent/CA2970440A1/en active Pending
- 2015-12-23 HU HUE19172397A patent/HUE066020T2/hu unknown
- 2015-12-23 CA CA3224507A patent/CA3224507A1/en active Pending
- 2015-12-23 RS RS20240357A patent/RS65343B1/sr unknown
- 2015-12-23 RU RU2022102250A patent/RU2022102250A/ru unknown
- 2015-12-23 RU RU2017121892A patent/RU2768019C2/ru active
- 2015-12-23 SI SI201531999T patent/SI3560953T1/sl unknown
2017
- 2017-05-10 IL IL252208A patent/IL252208B/en unknown
- 2017-05-16 ZA ZA2017/03381A patent/ZA201703381B/en unknown
- 2017-05-23 CL CL2017001314A patent/CL2017001314A1/es unknown
- 2017-06-23 US US15/632,119 patent/US10174099B2/en active Active
- 2017-06-23 US US15/631,948 patent/US10098926B2/en active Active
2018
- 2018-06-29 US US16/024,445 patent/US10981970B2/en active Active
- 2018-11-13 CL CL2018003217A patent/CL2018003217A1/es unknown
- 2018-11-13 CL CL2018003216A patent/CL2018003216A1/es unknown
- 2018-12-06 US US16/211,538 patent/US11034750B2/en active Active
2019
- 2019-11-14 JP JP2019206023A patent/JP6909844B2/ja active Active
2020
- 2020-02-07 US US16/785,467 patent/US20200181232A1/en not_active Abandoned
- 2020-08-06 AU AU2020213352A patent/AU2020213352B2/en active Active
- 2020-12-01 JP JP2020199333A patent/JP7514746B2/ja active Active
2021
- 2021-10-19 JP JP2021170769A patent/JP2022002546A/ja not_active Withdrawn
2022
- 2022-07-12 AU AU2022205170A patent/AU2022205170B2/en active Active
- 2022-07-12 AU AU2022205169A patent/AU2022205169B2/en active Active
2023
- 2023-01-24 US US18/158,754 patent/US12398194B2/en active Active
2024
- 2024-03-05 JP JP2024032851A patent/JP2024055976A/ja active Pending
- 2024-12-10 AU AU2024278248A patent/AU2024278248A1/en active Pending
2025
- 2025-07-25 US US19/281,399 patent/US20250353893A1/en active Pending

Also Published As

Publication number	Publication date
AU2015370679A1 (en)	2017-06-01
IL301458A (en)	2023-05-01
HRP20240357T1 (hr)	2024-06-07
EP4368704A2 (en)	2024-05-15
JP2024055976A (ja)	2024-04-19
US10174099B2 (en)	2019-01-08
US20250353893A1 (en)	2025-11-20
PL3237442T3 (pl)	2020-02-28
IL252208A0 (en)	2017-07-31
JP2021036913A (ja)	2021-03-11
MX2017006233A (es)	2017-10-24
SI3560953T1 (sl)	2024-05-31
KR102085349B1 (ko)	2020-03-06
SMT202400134T1 (it)	2024-05-14
US11034750B2 (en)	2021-06-15
RU2017121892A (ru)	2019-01-24
SG10202111107RA (en)	2021-11-29
CL2018003217A1 (es)	2019-02-01
HUE046262T2 (hu)	2020-02-28
ES2744910T3 (es)	2020-02-26
IL274903B (en)	2022-07-01
CN114107212A (zh)	2022-03-01
CN107002045A (zh)	2017-08-01
RS65343B1 (sr)	2024-04-30
EP3237442A1 (en)	2017-11-01
AU2022205169B2 (en)	2024-09-26
CA3224507A1 (en)	2016-06-30
US20170340705A1 (en)	2017-11-30
JP2020022508A (ja)	2020-02-13
DK3237442T3 (da)	2019-09-23
KR20200003939A (ko)	2020-01-10
IL292508B1 (en)	2023-04-01
AU2020213352B2 (en)	2022-08-18
KR20170092695A (ko)	2017-08-11
AU2022205169A1 (en)	2022-09-15
FI3560953T3 (fi)	2024-03-21
KR102376242B1 (ko)	2022-03-21
DK3560953T3 (da)	2024-04-02
AU2022205170A1 (en)	2022-09-15
US10981970B2 (en)	2021-04-20
IL252208B (en)	2021-10-31
CA2970440A1 (en)	2016-06-30
AU2020213352A1 (en)	2020-08-27
PT3237442T (pt)	2019-09-26
PT3560953T (pt)	2024-03-26
ZA201703381B (en)	2018-08-29
US20200181232A1 (en)	2020-06-11
NZ731778A (en)	2024-02-23
EP4368704A3 (en)	2024-05-29
JP6633081B2 (ja)	2020-01-22
LT3560953T (lt)	2024-05-10
CL2017001314A1 (es)	2017-12-15
JP6909844B2 (ja)	2021-07-28
AU2024278248A1 (en)	2025-01-30
KR20230152824A (ko)	2023-11-03
JP2022002546A (ja)	2022-01-11
JP7514746B2 (ja)	2024-07-11
KR20220129684A (ko)	2022-09-23
BR112017013690A2 (pt)	2018-03-06
IL292508A (en)	2022-06-01
US11091532B2 (en)	2021-08-17
EP3560953B1 (en)	2024-01-31
HUE066020T2 (hu)	2024-07-28
AU2022205170B2 (en)	2025-02-27
EP3560953A1 (en)	2019-10-30
KR102376244B1 (ko)	2022-03-21
AU2015370679C1 (en)	2020-09-10
ES2976197T3 (es)	2024-07-26
RU2768019C2 (ru)	2022-03-23
US20170369550A1 (en)	2017-12-28
AU2015370679B2 (en)	2020-05-21
US20170340704A1 (en)	2017-11-30
US12398194B2 (en)	2025-08-26
KR20210098557A (ko)	2021-08-10
US20230331810A1 (en)	2023-10-19
US20180371054A1 (en)	2018-12-27
RU2022102250A (ru)	2022-03-23
DK3560953T5 (da)	2024-09-02
US20190161531A1 (en)	2019-05-30
SG11201704084VA (en)	2017-06-29
CN107002045B (zh)	2025-10-21
WO2016102965A1 (en)	2016-06-30
EP3237442B1 (en)	2019-07-10
RU2017121892A3 (pl)	2019-05-28
KR20210098556A (ko)	2021-08-10
IL292508B2 (en)	2023-08-01
JP2018501794A (ja)	2018-01-25
IL274903A (en)	2020-07-30
US10098926B2 (en)	2018-10-16
CL2018003216A1 (es)	2019-02-01

Publication	Publication Date	Title
HUE046262T2 (hu)	2020-02-28	Sejt
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3006072T3 (da)	2021-10-25	Karadgang
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
PL3509156T3 (pl)	2020-10-19	Roztwór elektrolitu
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
EP4011484C0 (en)	2025-09-24	CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE112015001633A5 (de)	2017-02-23	Betätigungsaktuator
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
ES1133830Y (es)	2015-02-12	Columbario
DE112015005055A5 (de)	2017-08-03	Gargerätevorrichtung
EP3171776C0 (de)	2023-11-08	Abbildungsanordnung
DK3091875T3 (da)	2019-10-14	Vipbar taburet
UA30460S (uk)	2015-09-25	Акумуляторна батарея
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
DE112015004618A5 (de)	2017-09-07	Garnitur
FI10894U1 (fi)	2015-06-11	Putkieristyskouru
ES1136185Y (es)	2015-09-03	Huevera
FI10806U1 (fi)	2015-03-13	Ajoestepylväs